A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.
Cancer is one of the leading causes of death worldwide. In 2018, there were around 18 million new cases and 9.5 million cancer-related deaths. By 2040, those numbers are expected to increase to 29.5 million and 16.4 million respectively. With the rise in new cases comes increased expenditures for cancer care.
Cancer research is important because the better we understand this disease, the more progress we will make toward diminishing the detrimental impacts of cancer on patients, families and society.
To find better ways to prevent, diagnose and treat cancer, we need to better understand how cancers are being managed in real clinical settings: the association between different treatment strategies and patients’ clinical outcomes, healthcare resource utilization (HRU), adverse events, as well as economic outcomes. More and more researchers are turning to actionable insights derived from the PINC AI™ Healthcare Database (PHD) to further our knowledge in cancer research.
As of May 1, 2023, the PHD has coalesced insights from more than 1,263 sites in the U.S. to fuel evidence- and population-based cancer research.
The PHD has:
1. What are the costs and HRU associated with acute myeloid leukemia (AML) patients receiving intensive induction chemotherapy?
Acute myeloid leukemia (AML) is a rare malignancy with a poor prognosis and in the U.S. It is most frequently diagnosed among individuals 65-74 years old. The current standard of care for AML consists of induction chemotherapy to reduce the leukemic burden and produce complete remission, followed by consolidation therapy to eradicate residual disease and maintain remission.
AML is already known to be associated with substantial HRU and healthcare cost, but what are the hospital-based costs and HRU associated with intensive induction chemotherapy among patients with newly diagnosed AML? In a recent study using PHD data, researchers sought to answer this question in inpatient or hospital-based outpatient visit settings.
They found:
In the U.S. hospital setting, substantial HRU and costs are associated with intensive induction chemotherapy for AML patients and are driven by inpatient hospitalizations.
2. Are hospital resources being utilized efficiently, appropriately and cost effectively?
Medical resources may be expensive and in short supply, and efficient use of resources is a key measure when determining overall healthcare quality. Identifying potential cases of inappropriate utilization is important for health systems and patients alike but can be a challenging task for many hospitals. Therefore, a more generalizable, universally available and fully scalable methodology using an administrative database is needed.
In a recent study, researchers explored standard and novel methods to identify potential inefficiencies or resource misutilization using PHD data. As an example, they looked at the utilization of computed tomography (CT) scans in patients diagnosed with prostate cancer.
Researchers found that misutilization (i.e., under- or over-utilization) of CT scans of the pelvis and abdomen without contrast were significantly lower among hospitals with larger patient volumes.
The approach proposed in the study could be used across diseases and resources, providing a metric to identify potential misutilization against industry standards.
3. Are clinical outcomes, costs and healthcare resources impacted in Merkel cell carcinoma (MCC) patients treated with immune checkpoint inhibitors (ICIs)?
MCC is a rare, aggressive skin cancer with a poor prognosis. Therefore, limited information is available on treatment outcomes among metastatic MCC (mMCC) patients. Because the PHD is the largest geographically diverse hospital administrative database in the U.S., researchers were able to compare patient characteristics, comorbidities, adverse events (AEs), treatment persistence, HRU and costs in patients with mMCC treated with immune checkpoint inhibitors (ICIs) versus standard of care chemotherapy in a recent study.
In a real-world setting, patients with mMCC receiving ICIs had higher treatment persistence over 90 days, shorter inpatient LOS and similar departmental costs (excluding pharmacy costs) than those receiving chemotherapy.
Life sciences organizations, researchers and clinicians are continuously looking for ways to use RWD to help identify patients and address the gap between disease diagnosis and treatment. This requires much earlier identification of specific disease states by looking for subtle signs that are often found in the unstructured narrative or clinician notes in patient charts.
The PHD data combined with unstructured data collected via natural language processing (NLP) technology is well suited for uncovering these details helping to identify which risk factors and clinical signs and symptoms are most predictive of subsequent disease development.
For example:
Greater knowledge as well as breakthroughs in prevention, early detection, screening, diagnosis and treatment are often the results of research and discoveries made by researchers in a wide array of disciplines over decades and even generations. Such research relies on large amounts of standardized data as well as partnerships and collaborations with researchers, clinicians, data scientists and patients.
Combining real-world research findings with a willingness to take evidence-based actions can help relieve the strain on healthcare, help improve patient care and outcomes, and help reduce costs.
The insights you need to stay ahead in healthcare: Subscribe to Premier’s Power Rankings newsletter and get our experts’ original content delivered to your inbox once a month.